Slingshot members are tracking this event:

Oral Ozanimod Showed Histologic Improvements in Patients with Ulcerative Colitis in the Phase 2 TOUCHSTONE Trial

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Clinical Data In patients with moderate to severe ulcerative colitis, histologic improvement was greater with ozanimod 1 mg versus placebo at weeks 8 and 32.  A greater proportion of patients achieved histologic remission at week 32 with ozanimod 1 mg versus placebo.  TOUCHSTONE met its primary endpoint and secondary endpoints of safety and efficacy with statistical significance for patients on the 1 mg dose of ozanimod versus placebo.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 18, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Ulcerative Colitis, Ozanimod, Touchstone Trial, Phase 2 Data